Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Information source: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia
Intervention: pravastatin sodium (Drug); idarubicin (Drug); cytarabine (Drug); laboratory biomarker analysis (Other)
Phase: N/A
Status: Completed
Sponsored by: Fred Hutchinson Cancer Research Center Official(s) and/or principal investigator(s): Mazyar Shadman, Principal Investigator, Affiliation: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Summary
This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating
patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes. Drugs
used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
Pravastatin sodium may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving idarubicin and cytarabine together with pravastatin sodium
may kill more cancer cells.
Clinical Details
Official title: Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of participants with good CRNumber of participants with TRM
Secondary outcome: Relapse free survivalOverall survival Biomarkers associated with clinical responses
Detailed description:
PRIMARY OBJECTIVES:
I. To assess the rate of achieving a "good complete response (CR)" after treating patients
with newly diagnosed acute myeloid leukemia (AML) with idarubicin, cytarabine and
pravastatin (pravastatin sodium) (IAP).
II. To determine the toxicity (death within 28 days of starting therapy = treatment related
mortality or "TRM") with IAP in newly-diagnosed AML.
SECONDARY OBJECTIVES:
I. To determine rates of complete remission (CR), remission with incomplete blood count
recovery (CRi), partial remission (PR), relapse-free survival and overall survival.
II. To identify biomarkers (ie. changes in serum cholesterol) associated with clinical
responses.
OUTLINE:
Patients receive pravastatin sodium orally (PO) once daily (QD) on days 1-8, idarubicin
intravenously (IV) over 10-15 minutes on days 4-6, and cytarabine IV continuously on days
4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and
then annually for 3 years.
Eligibility
Minimum age: 18 Years.
Maximum age: 74 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of acute myeloid leukemia by
World Health Organization (WHO) 2008 criteria, including patients with >= 20% blasts
in the bone marrow or peripheral blood (except acute promyelocytic leukemia), or
myelodysplastic syndrome refractory anemia with excess blasts (RAEB)-2 by WHO
classification or advanced myeloproliferative neoplasm with >= 10% blasts in the bone
marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) CMML-2
by WHO 2008 classification
- Untreated AML or high-risk myelodysplastic syndrome (MDS) and a simplified TRM score
of =< 9. 2
- Bilirubin < 2. 0 mg/ml
- Any creatinine value is acceptable
- Any performance status is eligible
- Life expectancy otherwise > 1 year
- Patients are not excluded based on cardiac history
- Females of childbearing potential must have a negative serum pregnancy test within 2
weeks prior to enrollment
- Patients must use an effective contraceptive method during the study and for a
minimum of 90 days after study treatment
- Capable of understanding the investigational nature, potential risks and benefits of
the study, and able to provide valid informed consent
Locations and Contacts
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98109, United States
Additional Information
Starting date: May 2013
Last updated: March 3, 2015
|